Toxicity, outcomes, and deaths
| Toxicity and outcomes (1-y cumulative incidence) . | ||
|---|---|---|
| . | All patients (N = 39) . | HL subset (N = 31) . |
| . | % (range, 95% CI) . | % (range, 95% CI) . |
| Acute GVHD | ||
| Grade 2-4 | 44 (28-59) | 45 (27-62) |
| Grade 3-4 | 23 (11-37) | 26 (13-55) |
| Grade 4 | 13 (5-25) | 13 (4-27) |
| Chronic GVHD | 41 (22-60) | 33 (13-55) |
| Hepatic SOS (3-mo cumulative incidence) | 8 (2-19) | 6 (1-19) |
| OS | 89 (74-96) | 90 (71-97) |
| PFS | 76 (56-87) | 74 (50-88) |
| CIR | 14 (4-29) | 16 (3-36) |
| NRM | 11 (3-23) | 10 (3-25) |
| Toxicity and outcomes (1-y cumulative incidence) . | ||
|---|---|---|
| . | All patients (N = 39) . | HL subset (N = 31) . |
| . | % (range, 95% CI) . | % (range, 95% CI) . |
| Acute GVHD | ||
| Grade 2-4 | 44 (28-59) | 45 (27-62) |
| Grade 3-4 | 23 (11-37) | 26 (13-55) |
| Grade 4 | 13 (5-25) | 13 (4-27) |
| Chronic GVHD | 41 (22-60) | 33 (13-55) |
| Hepatic SOS (3-mo cumulative incidence) | 8 (2-19) | 6 (1-19) |
| OS | 89 (74-96) | 90 (71-97) |
| PFS | 76 (56-87) | 74 (50-88) |
| CIR | 14 (4-29) | 16 (3-36) |
| NRM | 11 (3-23) | 10 (3-25) |
| Deaths . | ||||||
|---|---|---|---|---|---|---|
| Pt. no. . | Histology . | Donor source . | Graft source . | Interval between PD-1 and HSCT, d . | Day of death . | Complications . |
| 3 | Mixed cellularity HL | MMUD | PB | 17 | 100 | Febrile syndrome, hyperacute grade 4 acute GVHD, bacteremia, acute kidney injury, hypoxic respiratory failure |
| 8 | Nodular sclerosing HL | MUD | PB | 100 | 123 | Febrile syndrome, hyperacute grade 4 acute GVHD, bacteremia, diffuse alveolar hemorrhage, posterior reversible encephalopathy syndrome |
| 14 | Nodular sclerosing HL | Haploidentical | BM | 156 | 51 | Severe SOS and renal failure requiring central veno-venous hemofiltration (CVVH) |
| 18 | Enteropathy-associated T-cell lymphoma | MUD | PB | 49* | 35 | Grade 4 acute GVHD, hepatic encephalopathy, and hypotension |
| Deaths . | ||||||
|---|---|---|---|---|---|---|
| Pt. no. . | Histology . | Donor source . | Graft source . | Interval between PD-1 and HSCT, d . | Day of death . | Complications . |
| 3 | Mixed cellularity HL | MMUD | PB | 17 | 100 | Febrile syndrome, hyperacute grade 4 acute GVHD, bacteremia, acute kidney injury, hypoxic respiratory failure |
| 8 | Nodular sclerosing HL | MUD | PB | 100 | 123 | Febrile syndrome, hyperacute grade 4 acute GVHD, bacteremia, diffuse alveolar hemorrhage, posterior reversible encephalopathy syndrome |
| 14 | Nodular sclerosing HL | Haploidentical | BM | 156 | 51 | Severe SOS and renal failure requiring central veno-venous hemofiltration (CVVH) |
| 18 | Enteropathy-associated T-cell lymphoma | MUD | PB | 49* | 35 | Grade 4 acute GVHD, hepatic encephalopathy, and hypotension |
PB, peripheral blood; SOS, sinusoidal obstruction syndrome.
Received ipilimumab concurrently with anti-PD-1 therapy. The last dose of ipilimumab was also 49 d prior to HSCT.